Copertina

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
di: Yewan Park, et al.
Pubblicazione: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
di: Carolin V. Schneider, et al.
Pubblicazione: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
di: Nobuharu Tamaki, et al.
Pubblicazione: (2025)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
di: Nobuharu Tamaki, et al.
Pubblicazione: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
di: Nabil Noureddin, et al.
Pubblicazione: (2024)

Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice—Authors' Reply
di: Nikolaj Torp, et al.
Pubblicazione: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
di: Qiang Hu, et al.
Pubblicazione: (2024)

Prevalence and risk factors of metabolic dysfunction‐associated steatotic liver disease in south Central Uganda: A cross‐sectional survey
di: Rocio Enriquez, et al.
Pubblicazione: (2024)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
di: María Hernández‐Pérez, et al.
Pubblicazione: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
di: Richie Manikat, et al.
Pubblicazione: (2024)

Editorial: MetALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan?
di: Hannes Hagström, et al.
Pubblicazione: (2025)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
di: Mohamed I. Elsaid, et al.
Pubblicazione: (2024)

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease
di: Mohamad Jamalinia, et al.
Pubblicazione: (2024)

Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All‐Cause Mortality in MetALD
di: Zhe‐Kun Xiong, et al.
Pubblicazione: (2025)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
di: Carolin V. Schneider, et al.
Pubblicazione: (2024)

Short‐term reduction of dietary gluten improves metabolic‐dysfunction associated steatotic liver disease: A randomised, controlled proof‐of‐concept study
di: Angelo Armandi, et al.
Pubblicazione: (2024)

Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study
di: Federica Tavaglione, et al.
Pubblicazione: (2025)

Letter on ‘Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study’
di: Muhammad Abubakr, et al.
Pubblicazione: (2025)

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study
di: Nipun Verma, et al.
Pubblicazione: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
di: Richie Manikat, et al.
Pubblicazione: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
di: Abdel‐Aziz Shaheen, et al.
Pubblicazione: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
di: Nobuharu Tamaki, et al.
Pubblicazione: (2024)

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population
di: Antonio De Vincentis, et al.
Pubblicazione: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
di: Manya Prasad, et al.
Pubblicazione: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
di: Samer Gawrieh, et al.
Pubblicazione: (2024)

Paediatric‐onset immune‐mediated inflammatory disease is associated with an increased mortality risk—A nationwide study
di: Mikkel Malham, et al.
Pubblicazione: (2024)

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
di: Parminder Kaur, et al.
Pubblicazione: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
di: Yaomin Wang, et al.
Pubblicazione: (2024)

Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
di: Pojsakorn Danpanichkul, et al.
Pubblicazione: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
di: Sung Won Chung, et al.
Pubblicazione: (2024)

Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
di: Donghee Kim, et al.
Pubblicazione: (2024)

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
di: Shusuke Kumazaki, et al.
Pubblicazione: (2024)

Socio‐economic association of alcohol use disorder and cardiovascular and alcohol‐associated liver disease from 2010 to 2019
di: Pojsakorn Danpanichkul, et al.
Pubblicazione: (2024)

Review article: Oesophageal disorders in chronic liver disease
di: Francisco Idalsoaga, et al.
Pubblicazione: (2024)

UK guideline on the transition and management of childhood liver diseases in adulthood
di: Deepak Joshi, et al.
Pubblicazione: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
di: Zhuo Li, et al.
Pubblicazione: (2024)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
di: Lukas Hartl, et al.
Pubblicazione: (2024)

Racial and ethnic disparities in post‐liver transplant outcomes for patients with acute‐on‐chronic liver failure: An analysis of the UNOS database
di: David Uihwan Lee, et al.
Pubblicazione: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
di: Ivan Arcari, et al.
Pubblicazione: (2024)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
di: Nina Dominik, et al.
Pubblicazione: (2024)